NCT03776812 2025-10-07
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Corcept Therapeutics
Phase 2 Completed
Clinical Trials
10 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05983276 2024-02-08
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Loyola University
Phase 2 Recruiting
NCT05310344 2022-04-04
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04815408 2021-03-25
PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04590625 2020-10-19
Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer
Zhongshan Hospital Xiamen University
Phase 2 Unknown
NCT03942068 2019-05-08
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT00499252 2018-01-11
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00585052 2018-01-05
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
University of Iowa
Phase 2 Terminated
NCT01821859 2013-07-26
Abraxane/Bevacizumab
OHSU Knight Cancer Institute
Phase 2 Terminated